\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Clinico-Hematological Study of Pancytopenia with Special Reference to Idiopathic Pancytopenia}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2014-01 2017-01-15 (revised: Jan 2014-February 2015 15 January 2017)} \def\TheID{\makeatother } \def\TheDate{2014-01 2017-01-15} \title{Clinico-Hematological Study of Pancytopenia with Special Reference to Idiopathic Pancytopenia} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Hema Goyal} \author[2]{Dr. Vijai Tilak} \author[3]{Dr. Ankush Singhal} \affil[1]{ INSTITUTE OF MEDICAL SCIENCES, BANARAS HINDU UNIVERSITY} \renewcommand\Authands{ and } \date{\small \em Received: 11 December 2016 Accepted: 5 January 2017 Published: 15 January 2017} \maketitle \begin{abstract} Background: Pancytopenia may present with different clinical scenario in daily practice. The present study was carried out to find the various causes of pancytopenia in Varanasi and adjoining areas with special reference to Idiopathic pancytopenia. Material & Method: It was a prospective study conducted over a period of one year (Jan 2014-February 2015) at Department of Pathology in Institute of Medical sciences, Banaras Hindu University, Varanasi. Patients presenting with pancytopenia were included in the study. A provisional diagnosis was made on the clinical findings. Extensive laboratory work up (including LFT, RFT, Serology etc) was carried out to find the cause of pancytopenia in all the patients. Bone marrow aspiration was done in all the cases as a routine procedure. Bone marrow biopsy was done in 48 cases where indicated. Result: A total of 140 patients presented with pancytopenia. Among the causes, Aplastic anemia was the most common cause (31.4%) followed by Megaloblastic anemia (22.1%) The third common cause was Myelodysplastic syndrome (MDS) (12.9%) followed by Acute leukemia (11.4%). Other causes were hypersplenism (4.3%), kala azar (2.1%), drug induced (2.1%), two cases each of HIV (1.4%), myelofibrosis (1.4%), lymphoma (1.4%) & multiple myeloma (1.4%). One case each of ITP (0.7%), SLE (0.7%) and Fanconi anemia (0.7%). Idiopathic pancytopenia constituted 5% (7 cases) of the total. On follow up of patients with idiopathic pancytopenia at 6 months, all the seven patients were having persistent pancytopenia. They were labeled as ICUS (Idiopathic cytopenia of undetermined significance (ICUS)). One patient was hospitalized with complains of generalized body weakness and few episodes of malena. Thorough work up was done to look for any cause of pancytopenia but no cause was identified and patient died due to complication of pancytopenia (due to hemorrhagic shock) in one month course and hence ?"Idiopathic fatal pancytopenia?" term was coined for the patient. \end{abstract} \keywords{pancytopenia, aplastic anemia, myelodysplastic syndrome(MDS), idiopathic pancytopenia, idiopathic cytopenia of undetermined significance(ICUS).} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \par Among the causes, Aplastic anemia was the most common cause (31.4\%) followed by Megaloblastic anemia (22.1\%) The third common cause was Myelodysplastic syndrome (MDS) (12.9\%) followed by Acute leukemia (11.4\%). Other causes were hypersplenism (4.3\%), kala azar (2.1\%), drug induced (2.1\%), two cases each of HIV (1.4\%), myelofibrosis (1.4\%), lymphoma (1.4\%) \& multiple myeloma (1.4\%). One case each of ITP (0.7\%), SLE (0.7\%) and Fanconi anemia (0.7\%). Idiopathic pancytopenia constituted 5\% (7 cases) of the total. On follow up of patients with idiopathic pancytopenia at 6 months, all the seven patients were having persistent pancytopenia. They were labeled as ICUS (Idiopathic cytopenia of undetermined significance (ICUS)). One patient was hospitalized with complains of generalized body weakness and few episodes of malena. Thorough work up was done to look for any cause of pancytopenia but no cause was identified and patient died due to complication of pancytopenia (due to hemorrhagic shock) in one month course and hence "Idiopathic fatal pancytopenia" term was coined for the patient. Remaining six patients were followed up at 12 months, 03 patients were having persisting pancytopenia without any specific complaints and remaining 03 patients died, for which cause is unknown. Conclusion: Pancytopenia is a common haematological problem encountered in clinical practice.The natural history of patients with ICUS is largely unknown and appears to be highly variable. ICUS patients require long term follow up to assess the evolution. "Idiopathic fatal pancytopenia (IFP)" is an emerging new entity with a grave prognosis. Further research may elucidate the underlying pathology \& potential drugs to halt the inevitable fatal outcome. \section[{I. Introduction}]{I. Introduction}\par ancytopenia is the simultaneous occurence of anemia, leucopenia and thrombocytopenia. Many disease processes involve the bone marrow primarily or secondarily resulting in pancytopenia. Pancytopenia can develop due to decrease in hematopoietic cell production as a result of destruction of marrow tissue by toxins, suppression of normal marrow growth and differentiation or due to replacement of bone marrow by abnormal or malignant tissue. The marrow may be hypocellular or hypercellular. Bone marrow examination usually provides the diagnosis in these cases. Few cases where exact diagnosis could not be made even after an exhaustive work up, these cases were regarded as Idiopathic pancytopenia. We followed up these cases at 6 month and 12 month. We particularly emphasized on these cases with the comparative study with other diagnosis. No study undertaken in this regard in India yet. \section[{II. Material and Method}]{II. Material and Method} \section[{P}]{P}( D D D D ) \section[{C}]{C}\par The present study was a prospective study. A total of 140 patients presenting with pancytopenia were enrolled in the study. Approval from Ethical Committee and patient consent were taken. These 140 patients were divided into two age groups : Children (<18 years) \& Adult (?18 years). The inclusion criteria for pancytopenia were hemoglobin (Hb) less than 10 gm/dL, total leukocyte count (TLC) less than 4000/cumm and platelet count less than 150000/cumm. A detailed clinical history and physical examination was undertaken in all the cases. A provisional diagnosis was made on these clinical findings. Peripheral smear examination and reticulocyte count was done. Samples of bone marrow aspiration were taken from the patients admitted in the Department of Medicine and Pediatrics of Sir Sunderlal Hospital, Banaras Hindu University, Varanasi. All the patients were checked for having any major clotting disorder before undergoing any procedure. BMA was performed by the standard technique using Salah needle from the posterior iliac crest under local anesthesia with standard aseptic precautions. Leishman stain was used to stain all bone marrow smears. BM aspirate for cytogenetics was takrn into a sodium heparin tube. Excess aspirate was used to make particle clot preparations or placed in an EDTA tube for making additional smears. Special cytochemical stains were undertaken in cases of leukemia. rk-39 dipstick test was done in all cases of Kala-azar. Bone marrow biopsy was done in 48 cases where the diagnosis was doubtful on aspiration. Chromosomal breakage study was advised in a suspected case of Fanconi anemia. Immunohistochemistry (IHC) with CD34 was done on biopsy section in certain cases to enumerate the exact count of blast. We followed the algorithm presented in figure 1. The mean age of patients of Idiopathic pancytopenia was 37.6±22.7 years. There were 3 children and 4 adults. The male to female ratio was 6:1. The mean Hb (gm/dl) was 6.5±2.6(4.3-10.6), mean TLC(/cumm) was 2743±929(1100-3800), mean Platelet count (/cumm) was 39100±29260 (11000-86000) and mean MCV (fl) was 89.7±11(72-106).\par In our study, 7 cases presented with pancytopenia with normocellular marrow. No signs of dysplasia or increase in blast count were noted. Bone marrow biopsy was undertaken for these patients. No bone marrow fibrosis was noted. No CD34 positive cells (blast) were seen in the bone marrow by IHC. Conventional cytogenetics was performed on bone marrow aspirate and it was normal in all the cases. These cases did not respond to Vitamin B12 and folic acid therapy. Serum biochemical parameters and coagulation profile was within normal limit. \section[{Global Journal of}]{Global Journal of} \section[{Medical Research}]{Medical Research}\par Volume XVII Issue I Version I( D D D D )\par Autoimmune profile was conducted for these patients and was within normal limit. Radiological investigations were done to rule out any specific pathology. On follow up at 6 months all seven cases were having persistent pancytopenia. These cases were diagnosed as ICUS (idiopathic cytopenia of undetermined significance). One patient presented with generalized body weakness and few episode of malena in the past. The patient was hospitalized and further work up was started to find the cause of malena and pancytopenia. In due course, patient had declining trend in the hematological parameters and started bleeding and went into hemorrhagic shock and died. No cause of pancytopenia could be identified and hence we coined the term Idiopathic fatal pancytopenia for this patient. Remaining six patients were followed up at 12 months, 3 patients were having persistent pancytopenia and three patients died, for those the cause is not known as they were not available for any work up. The most common presenting symptom was generalized body weakness in 126 patients (90\%). The most common sign was pallor in 137 cases (97.8\%)\par The various causes of pancytopenia were divided into five categories for further evaluation as Aplasticanemia, Megaloblastic anemia, Infiltrative disorders[including acute leukemia-myeloid(AML) and lymphoid(ALL), myelodysplastic syndrome(MDS), lymphoma, multiple myeloma], Others [including, Fanconi anemia, hypersplenism, kala-azar, HIV, septicemia, drug induced causes, SLE, myelofibrosis and immune mediated thrombocytopenic purpura(ITP)] and Unknown causes(idiopathic pancytopenia) In our study, MCV was significantly increased in cases of pancytopenia due to megaloblastic anemia (24 out of 31 cases) where as it was within normal range in other causes of pancytopenia due to aplastic anemia and infiltrative causes. The correlation between megaloblastic anemia and macrocytic anemia was found to be significant in our study with p value <0.05. Aplastic anemia and other infiltrative conditions were associated with normocytic anemia which was found to be significant. Red cell distributon width RDW-CV was significantly increased in cases of pancytopenia due to megaloblastic anemia as compared to other causes which had normal RDW values. Mean platelet volume (MPV) was also significantly increased in cases of megaloblastic anemia as compared to other causes of pancytopenia (aplastic anemia, infiltrative lesion). \section[{IV. Discussion}]{IV. Discussion}\par Pancytopenia is defined by reduction of all the three formed elements of blood below the normal reference range \hyperref[b0]{[1]} . Pancytopenia is a common hematological finding with different clinical scenario.\par In our study the male: female ratio was 1.37:1. This is in agreement with other studies shown in (table \hyperref[tab_4]{5}). The male preponderance may be partly explained by increased exposure of male to environmental agents like agricultural pesticide \hyperref[b1]{[2]} . Few studies showed female preponderance \hyperref[b2]{[3,}\hyperref[b3]{4]} common sign was pallor (97.8\%) comparable to many other Indian studies (table \hyperref[tab_4]{5}).\par We compared our data with various International and Indian studies on pancytopenia (table \hyperref[tab_5]{6}). The most common cause in our study was Aplastic anemia. Many International studies \hyperref[b4]{[5,}\hyperref[b5]{6,}\hyperref[b6]{7,}\hyperref[b7]{8,}\hyperref[b8]{9,}\hyperref[b9]{10,}\hyperref[b11]{11,}\hyperref[b12]{12]} and national studies \hyperref[b3]{[4,}\hyperref[b13]{13,}\hyperref[b14]{14]} were in agreement with our finding as aplastic anemia as the most common cause of pancytopenia. Whereas few studies reported aplastic anemia as the second most common cause \hyperref[b15]{[15,}\hyperref[b16]{16,}\hyperref[b17]{17,}\hyperref[b18]{18,}\hyperref[b19]{19,}\hyperref[b20]{20,}\hyperref[b22]{22]} . Significant lymphocytosis was associated with aplastic anemia compared to other causes of pancytopenia. This finding was in agreement with SomaYadav et al., The pathophysiology of Aplastic anemia is believed to be immune mediated, with active destruction of blood forming cells by the lymphocytes . \hyperref[b3]{[4]} Megaloblastic anemia was the 2 nd common cause in our study whereas few Indian studies \hyperref[b18]{[18,}\hyperref[b19]{19,}\hyperref[b20]{20,}\hyperref[b21]{21,}\hyperref[b22]{22,}\hyperref[b23]{23,}\hyperref[b24]{24,}\hyperref[b25]{25]} and international studies \hyperref[b16]{[16,}\hyperref[b35]{34]} reported it as the first common cause. This may be due to the fact that ours is a tertiary care centre where many referral cases come which might have been treated with hematinic therapy previously.\par Out of 31 cases of Megaloblastic anemia, 26 had elevated LDH levels. All the cases improved with Vitamin B12 and folic acid therapy. R Para et al., and Evazi-ziaei et al., also observed increased LDH in megaloblastic anemia \hyperref[b25]{[25,}\hyperref[b26]{26]} . Lactate dehydrogenase enzymes is released during the The expected increase in LDH activity is the result of an accelerated turnover of bone marrow cells implying release of this enzyme from dividing or decaying cells. \hyperref[b27]{[27]} In MDS, most of the patients (75\%) were under the age 50years and 27\% of cases were below 20 years. Usually MDS is considered to be disease of elderly, but in the Indian series by S Nigam and Sudha Rani et al.,overall 75.5\% of individual (20/33) were of <50 years of age, 8 (21.6\%) of 33 patients were less than 20 years of age \hyperref[b29]{[28]} . This may be due to the fact that the incidence of MDS appears to be increasing over the past decade due to recognition of the syndrome by the physician and hematopathologist.\par Acute leukemia is the 3 rd common cause in our study. Many Indian studies are in agreement with ours study. Sarod R etal., reported acute leukemia as the 2 nd common cause. \hyperref[b30]{[29]} Various International studies reported few cases of pancytopenia with normal bone marrow (refer table \hyperref[tab_5]{6}). The frequency varies from 3.38\% to 10.5\%. No follow up was mentioned in them. No study has reported the phenomenon of Idiopathic pancytopenia. In our study we reported 5\% of these cases (pancytopenia with normal marrow and normal karyotype). We followed up these cases at 6 months and 12 months.\par ICUS is a recently proposed, provisional diagnostic category that recognizes patients who present with cytopenias of undetermined etiology \hyperref[b31]{[30,}\hyperref[b32]{31]} . The proposed criteria for diagnosing ICUS \hyperref[b31]{[30]} : a) Persistent cytopenia (for 6 months): hemoglobin <11 g/dl, neutrophils <1.5×109L, and platelets <100×109/L; b) No morphologic features of myelodysplasia c) Normal chromosome analysis and d) A detailed clinical history and investigation that excludes other secondary causes of cytopenias. The natural history of patients with ICUS is largely unknown and appears to be highly variable \hyperref[b33]{[32]} . Small studies indicate that some patients will go on to develop frank MDS or a related myeloid malignancy such as AML \hyperref[b34]{[33]} . Others may follow a more indolent course \hyperref[b35]{[34]} . ICUS cases require long term follow up to assess the evolution. In our study, all the seven cases fulfilled the criteria for ICUS. One patient was hospitalized for an extensive work up but within one month patient died due to hemorrhagic shock and no cause could be identified. The course of the patient was fatal and hence the patient was termed as Idiopathic fatal pancytopenia. Out of remaining six patients on follow up at 12 months, three patients were having persistent pancytopenia and another three patients were expired due to unknown cause. Hence the course of ICUS in our study was variable.\par The incidence of hypersplenism was 4.3\%. All cases were caused by portal hypertension secondary to liver cirrhosis. The incidence of pancytopenia caused by hypersplenism among international studies varied from 0 \% to 19\% \hyperref[b14]{[14,}\hyperref[b30]{29]} as well as among Indian studies varied from 0 \%-11.5\%. Our incidence of 4.3\% was within the range reported by various workers.\par Other infections included Septicemia and HIV. The incidence was 2.1\% in our study. There was a single case of septicemia presenting as pancytopenia in children. Two cases of HIV in adults were reported. The incidence of septicemia in various studies varied from 1.6\% to 17.2\% \hyperref[b3]{[4,}\hyperref[b19]{19,}\hyperref[b25]{25,}\hyperref[b36]{35]} and our data was within the aforementioned range.\par There was a single case of ITP in a 17 year old female with fever, pallor and petechial rashes. The incidence of ITP in our study was 0.7\%. In other studies, the incidence varied from 1.7-7.8\%. \hyperref[b23]{[23,}\hyperref[b25]{25,}\hyperref[b13]{13]} We also compared our data with various studies in children (table \hyperref[tab_6]{7}). Overall in adult(51.1\%) and children (58.4\%), aplastic anemia and megaloblastic anemia were the two most common causes of pancytopenia in our study.\par MCV, RDW-CV \& MPV was significantly increased in cases of pancytopenia due to megaloblastic anemia where as it was within normal range in other causes of pancytopenia due to aplastic anemia and infiltrative causes. Soma Yadav et al., \& Gupta et al., also assessed the role of MCV, RDW, MPV in cases of pancytopenia and they are in agreement with our study. \hyperref[b3]{[4,}\hyperref[b39]{38]} V. Conclusion\par Pancytopenia is a common hematological problem encountered in clinical practice. The most common cause of pancytopenia is Aplastic anemia followed by Megaloblastic anemia.ICUS cases require long term follow up. "Idiopathic fatal pancytopenia (IFP)" is an emerging new entity with a grave prognosis. We wish to sensitize the medical community \& the scientists to this rapidly fatal condition of unknown etiology.Further research may elucidate the underlying pathology \& potential drugs to halt the inevitable fatal outcome. \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.85\textwidth}} Year 2017\\ 10\end{longtable} \par \caption{\label{tab_0}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.03380681818181818\textwidth}P{0.04105113636363636\textwidth}P{0.024147727272727272\textwidth}P{0.07244318181818181\textwidth}P{0.08693181818181818\textwidth}P{0.12073863636363637\textwidth}P{0.06519886363636364\textwidth}P{0.053125\textwidth}P{0.048295454545454544\textwidth}P{0.050710227272727275\textwidth}P{0.0265625\textwidth}P{0.060369318181818184\textwidth}P{0.053125\textwidth}P{0.11349431818181817\textwidth}} Case no\tabcellsep Age\tabcellsep Sex\tabcellsep Hb(gm\%)\tabcellsep TLC(/Ul)\tabcellsep Platelet(/cumm)\tabcellsep MCV(fl)\tabcellsep \%Blast in PBS*\tabcellsep \%blast in BM\tabcellsep BM**\tabcellsep cellularity\tabcellsep BM fibrosis\tabcellsep CD34on BM cells\tabcellsep Cytogenetics\\ 1\tabcellsep 60\tabcellsep M\tabcellsep 4.3\tabcellsep 1100\tabcellsep 13000\tabcellsep 72\tabcellsep 0\tabcellsep 0\tabcellsep \multicolumn{2}{l}{NC***}\tabcellsep No\tabcellsep 0\tabcellsep 46,XY\\ 2\tabcellsep 17\tabcellsep F\tabcellsep 4.9\tabcellsep 3100\tabcellsep 39000\tabcellsep 84.1\tabcellsep 0\tabcellsep 0\tabcellsep \multicolumn{2}{l}{NC}\tabcellsep No\tabcellsep 0\tabcellsep 46,XX\\ 3\tabcellsep 65\tabcellsep M\tabcellsep 4.5\tabcellsep 2200\tabcellsep 11000\tabcellsep 106\tabcellsep 0\tabcellsep 0\tabcellsep \multicolumn{2}{l}{NC}\tabcellsep No\tabcellsep 0\tabcellsep 46,XY\\ 4\tabcellsep 11\tabcellsep M\tabcellsep 10.6\tabcellsep 2700\tabcellsep 84000\tabcellsep 90\tabcellsep 0\tabcellsep 0\tabcellsep \multicolumn{2}{l}{NC}\tabcellsep No\tabcellsep 0\tabcellsep 46,XY\\ 5\tabcellsep 17\tabcellsep M\tabcellsep 4.4\tabcellsep 2600\tabcellsep 75000\tabcellsep 90\tabcellsep 0\tabcellsep 0\tabcellsep \multicolumn{2}{l}{NC}\tabcellsep No\tabcellsep 0\tabcellsep 46,XY\\ 6\tabcellsep 55\tabcellsep M\tabcellsep 9.5\tabcellsep 3700\tabcellsep 29000\tabcellsep 86.2\tabcellsep 0\tabcellsep 0\tabcellsep \multicolumn{2}{l}{NC}\tabcellsep No\tabcellsep 0\tabcellsep 46,XY\\ 7\tabcellsep 38\tabcellsep M\tabcellsep 7.4\tabcellsep 3800\tabcellsep 23000\tabcellsep 100\tabcellsep 0\tabcellsep 0\tabcellsep \multicolumn{2}{l}{NC}\tabcellsep No\tabcellsep 0\tabcellsep 46,XY\end{longtable} \par {\small\itshape [Note: *PBS -peripheral blood smear, **BM-bone marrow, ***NC-normocellular]} \caption{\label{tab_1}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3} \par \begin{longtable}{P{0.45505050505050504\textwidth}P{0.21035353535353535\textwidth}P{0.1845959595959596\textwidth}} Symptoms \& signs\tabcellsep Number of patients (out of 140)\tabcellsep Percentage \%\\ Generalized body weakness\tabcellsep 126\tabcellsep 90\\ Pallor\tabcellsep 137\tabcellsep 97.8\\ Fever\tabcellsep 86\tabcellsep 61.4\\ Bleeding\tabcellsep 57\tabcellsep 40.7\\ Splenomegaly\tabcellsep 26\tabcellsep 18.6\\ Hepatomegaly\tabcellsep 16\tabcellsep 11.4\\ Lymph node\tabcellsep 15\tabcellsep 10.7\\ Pedal edema\tabcellsep 10\tabcellsep 7.14\end{longtable} \par \caption{\label{tab_2}Table 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{P{0.2478134110787172\textwidth}P{0.1412536443148688\textwidth}P{0.04212827988338192\textwidth}P{0.03221574344023324\textwidth}P{0.16355685131195336\textwidth}P{0.03965014577259475\textwidth}P{0.1511661807580175\textwidth}P{0.03221574344023324\textwidth}} Diagnosis\tabcellsep \multicolumn{3}{l}{MCV(fl) Chi square(DF=8) 55.78 P value <0.05}\tabcellsep \multicolumn{2}{l}{RDW-CV (\%) Chi square(DF=4) 31.26 P value <0.05}\tabcellsep \multicolumn{2}{l}{MPV(fl) Chi square(DF=4) 88.04 P value <0.05}\\ \tabcellsep < 83fl\tabcellsep 83-99fl\tabcellsep >99fl\tabcellsep 11.6-14\%\tabcellsep >14\%\tabcellsep 6-13fl\tabcellsep >13fl\\ Aplastic anemia\tabcellsep 3\tabcellsep 34\tabcellsep 7\tabcellsep 31\tabcellsep 13\tabcellsep 44\tabcellsep 0\\ Megaloblastic anemia\tabcellsep 4\tabcellsep 3\tabcellsep 24\tabcellsep 2\tabcellsep 29\tabcellsep 6\tabcellsep 25\\ Infiltrative disorders\tabcellsep 7\tabcellsep 22\tabcellsep 9\tabcellsep 14\tabcellsep 24\tabcellsep 36\tabcellsep 2\\ Others\tabcellsep 8\tabcellsep 11\tabcellsep 1\tabcellsep 8\tabcellsep 12\tabcellsep 18\tabcellsep 2\\ Unknown cause\tabcellsep 1\tabcellsep 4\tabcellsep 2\tabcellsep 3\tabcellsep 4\tabcellsep 7\tabcellsep 0\\ Number of cases\tabcellsep 23\tabcellsep 74\tabcellsep 43\tabcellsep 58\tabcellsep 82\tabcellsep 111\tabcellsep 29\end{longtable} \par \caption{\label{tab_3}Table 4 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{5} \par \begin{longtable}{P{0.23420698924731181\textwidth}P{0.11767473118279569\textwidth}P{0.14966397849462365\textwidth}P{0.19650537634408602\textwidth}P{0.1519489247311828\textwidth}} Study\tabcellsep \multicolumn{2}{l}{Age group M:F ratio}\tabcellsep Most common presentation\tabcellsep Most common sign\\ Deepak B.Kr et al., 3\tabcellsep 10-70yr\tabcellsep \multicolumn{2}{l}{1.0:1.8 Generalisedweakness (70.83\%)}\tabcellsep Pallor (45.83\%)\\ Soma Yadav et al., 4\tabcellsep All ages, <30yr-73.3\%\tabcellsep 1:1.2\tabcellsep Fever\tabcellsep Pallor\\ JigneshKumar et al., 21\tabcellsep 1-95yr\tabcellsep 1.6:1\tabcellsep Easy fatigability (79\%)\tabcellsep Pallor (100\%)\\ Nigam RK et al., 22\tabcellsep 2-80yr\tabcellsep \multicolumn{2}{l}{1.12:1 Generalized weakness, fever}\tabcellsep Pallor , splenomegaly\\ BhaskarBThakkar et al., 23\tabcellsep 13-86yr\tabcellsep 1.08:1\tabcellsep Generalisedweakness (97\%) and fever (70\%)\tabcellsep Pallor (100\%)\\ A Chhabra et al., 24\tabcellsep 6month -14yr\tabcellsep -\tabcellsep Bleeding manifestation (70.3\%) Fever (63.7\%)\tabcellsep Pallor (64.8\%)\\ Rajesh Para \&Shailajapara et al., 25\tabcellsep 3-90 yr\tabcellsep 1.1:1\tabcellsep Generalized weakness (51.7\%)\tabcellsep Pallor (25.9\%)\\ ArvindJain et al., 39\tabcellsep 2month-95yr\tabcellsep 2.6:1\tabcellsep -\tabcellsep -\\ Present study\tabcellsep 1-72yr\tabcellsep \multicolumn{2}{l}{1.37:1 Generalisedweakness (90\%)}\tabcellsep Pallor (97.8\%)\end{longtable} \par \caption{\label{tab_4}Table 5 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{6} \par \begin{longtable}{P{0.026332094175960347\textwidth}P{0.14465097067327548\textwidth}P{0.0007021891780256093\textwidth}P{0.036864931846344484\textwidth}P{0.09304006608839323\textwidth}P{0.07021891780256091\textwidth}P{0.15272614622057\textwidth}P{0.3254646840148699\textwidth}} \tabcellsep Study\tabcellsep \tabcellsep Country\tabcellsep No. of cases\tabcellsep Commonest cause of pancytopenia\tabcellsep Second common cause\tabcellsep Third common\\ \tabcellsep International\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep \multicolumn{2}{l}{agranulocytosis and aplastic}\tabcellsep Israel Europe 1987\tabcellsep \multicolumn{2}{l}{389 Aplastic anemia (52.7\%)}\tabcellsep MDS (10.5\%)\tabcellsep -\\ \tabcellsep \multicolumn{2}{l}{anemia study 5}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep \multicolumn{2}{l}{Keisu M and Ost A et al., 15}\tabcellsep Israel Europe 1990\tabcellsep 100\tabcellsep Neoplastic disease, Radiation therapy (32\%)\tabcellsep Aplastic anemia (19\%)\tabcellsep MDS (14\%)\\ \tabcellsep Hossain MA et al., 6\tabcellsep \tabcellsep Bangladesh1992\tabcellsep 50\tabcellsep Aplastic anemia\tabcellsep Chronic malaria, Kala-azar\tabcellsep Hypersplenism, Acute leukemia\\ \tabcellsep David Savage 16\tabcellsep G,\tabcellsep Zimbabwe 1997\tabcellsep 134\tabcellsep Megaloblastic anemia 48 (35.8\%)\tabcellsep Aplastic anemia 35 (26.1\%)\tabcellsep AIDS, Acute leukemia (11.82\%)\\ \tabcellsep \multicolumn{2}{l}{Mussarrat Niazi Fazl-i-Razig7}\tabcellsep Pakistan 2000\tabcellsep 89\tabcellsep Aplastic anemia (38.3\%)\tabcellsep Megaloblastic anemia (24.7\%)\tabcellsep -\\ \tabcellsep \multicolumn{2}{l}{Ishtiaq O Bagai HZ40}\tabcellsep Pakistan 2001\tabcellsep 100\tabcellsep Megaloblastic anemia 39 (39\%)\tabcellsep Hypersplenism secondary to cirrhosis 19 (19\%)\tabcellsep -\\ \tabcellsep \multicolumn{2}{l}{Khudairabbas et al., 17}\tabcellsep Iraq 2004\tabcellsep 105\tabcellsep Acute leukemia (30.47\%)\tabcellsep Aplastic anemia (17.14\%)\tabcellsep Non hodgkinslymphoma (14.47\%), megaloblastic anemia (13.33\%)\\ Volume XVII Issue I Version I\tabcellsep \multicolumn{3}{l}{Jha et al.,8 Lakhey et al., 9 Nepal 2010 Nepal 2008 Tajali khan et al.,10 Pakistan 2011 Pudasaini et al., 41 Nepal 2012 Anwar jebjan et al., 11 Pakistan 2012}\tabcellsep \multicolumn{2}{l}{148 Hypoplastic anemia (29\%) 54 Hypoplasticanemia (29.6\%) 160 Aplastic anemia (37.5\%) 57 Erythroid hyperplasia (21\%) 205 Aplastic anemia (28.3\%)}\tabcellsep Megaloblastic anemia (23.64\%) Hematological malignancies ( 27.78\%) Megaloblastic anemia (13.75\%) Megaloblastic anemia (12.3\%) Hematological malignancies (23.9\%)\tabcellsep Hematological malignancies(21.62\%), erythroid hyperplasia (19.6\%) and normal marrow in 3.38\% cases Megaloblastic anemia (24.1\%), erythroid hyperplasia (11.11\%), normocellular marrow in 7.41\% cases Acute leukemia (13.75\%), hypersplenism (10\%) Acute leukemia (12.3\%), infective pathology (12.3\%), ITP (10.5\%), microcytic anemia (7\%), hypoplastic anemia (5.3\%), MDS(3.5\%), Multiple myeloma (3.5\%), leishmaniasis(1.8\%) and normal marrow in 10.5\% Megaloblastic anemia (19.5\%), ITP (7.8\%), Iron deficiency anemia (4.4\%)\\ D D D D ) C\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Megaloblastic anemia (11.7\%), erythroid hyperplasia (20\%),\\ ( Medical Research\tabcellsep \multicolumn{3}{l}{Pathak et al.,12 Nepal 2013 N Verma and S Dash 13 India 1992}\tabcellsep \multicolumn{2}{l}{102 202 Aplastic anemia (40.6\%) Hypoplastic anemia (32.3\%)}\tabcellsep Hematological malignancies (19\%) Megaloblastic anemia (23.26\%)\tabcellsep Leishmaniasis, plasmacytosis, gaucher diseases, relative myeloid hyperplasia, eosinophilia, normocellular marrow in 5.8\% cases and 5.8\% cases remain inconclusive Acute leukemia (17.75\%)\\ Global Journal of\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_5}Table 6 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{7} \par \begin{longtable}{P{0.11489655172413792\textwidth}P{0.05862068965517241\textwidth}P{0.0633103448275862\textwidth}P{0.14655172413793105\textwidth}P{0.08206896551724138\textwidth}P{0.24972413793103448\textwidth}P{0.13482758620689655\textwidth}} Study\tabcellsep Country\tabcellsep \multicolumn{2}{l}{Number of cases AGE}\tabcellsep Most common cause\tabcellsep 2 nd Most common cause\tabcellsep 3 rd Most common cause\\ Gupta V et al.,36\tabcellsep India 2008\tabcellsep 105\tabcellsep \multicolumn{2}{l}{1.5-18yr Aplastic anemia (43.8\%)}\tabcellsep \multicolumn{2}{l}{Acute leukemia (25.7\%) Kala azar (9.5\%)}\\ \multicolumn{2}{l}{Chabbara A et al.,24 India 2012}\tabcellsep 111\tabcellsep 6 month -14 yr\tabcellsep Megaloblastic anemia (31.8\%)\tabcellsep \multicolumn{2}{l}{Malignancies (25.2\%) Infectious diseases (19.7\%)}\\ Jan AZ et al.,11\tabcellsep Pakistan 2013\tabcellsep 205\tabcellsep 6 month-14 year\tabcellsep Aplastic anemia (28.3\%)\tabcellsep Hematological malignancies (25.2\%)\tabcellsep Megaloblastic anemia (19.5\%)\\ Pathak et al.,12\tabcellsep Nepal 2013\tabcellsep 6(out of 48)\tabcellsep \multicolumn{2}{l}{<15yr Hypoplastic anemia (3cases)}\tabcellsep Hematological malignancies (2 cases)\tabcellsep Megaloblastic anemia (1 case)\\ Present Study\tabcellsep India 2015\tabcellsep 48(out of 140)\tabcellsep \multicolumn{2}{l}{<18yr Aplastic anemia (41.7\%)}\tabcellsep (16.7\%) Megaloblastic anemia\tabcellsep Acute leukemia (12.5\%) MDS (8.3\%)\end{longtable} \par \caption{\label{tab_6}Table 7 :}\end{figure} \footnote{© 2017 Global Journals Inc. (US)Year 2017} \footnote{© 2017 Global Journals Inc. (US)} \footnote{© 2017 Global Journals Inc. (US)Year 2017} \footnote{© 2017 Global Journals Inc. (US)Year 2017} \footnote{Clinico-Hematological Study of Pancytopenia with Special Reference to Idiopathic Pancytopenia © 2017 Global Journals Inc. (US)} \backmatter \par Vijai Tilak, Raini Jain 18 India 1999 77 Megaloblastic anemia (68\%) Aplastic anemia (7.7\%) \begin{bibitemlist}{1} \bibitem[Khan et al.]{b9}\label{b9} \textit{}, T A Khan , I A Khan , K Mahmood . \bibitem[ Rom J Intern Med ()]{b28}\label{b28} \textit{}, \textit{Rom J Intern Med} 1996. 34 (3-4) p. . \bibitem[Yadav et al. ()]{b3}\label{b3} ‘A Clinico-hematological study in cases of pancytopenia: correlation of automated cell counter parameters in various etiologies’. S Yadav , R Kushwaha , K Aggrawal , A K Tripathi , U S Singh , A K Kumar . \textit{Journal of Evolution of Medical and Dental Sciences} 2013. 2 (22) p. . \bibitem[Gupta et al. (2008)]{b37}\label{b37} ‘A study of clinico-hematological profiles of pancytopenia in children’. V Gupta , S Tripathi , V Tilak , B D Bhatia . \textit{Tropical Doctor} October 2008. 38 p. . \bibitem[Thakkar et al. ()]{b23}\label{b23} ‘A study of pancytopenia in adult patients more than 12 years of age in north west region of saurashtra’. B B Thakkar , N Bhavsar , Ukti , N J Trivedi , A S Agnihotri . \textit{National Journal of medical research} 2013. 3 (1) p. . \bibitem[Abbas et al. ()]{b17}\label{b17} K Abbas , A S Al-Zubaidy , M Rhaima . \textit{Pancytopenia adult patients at bagdhad teaching hospital}, 2011. 10 p. . \bibitem[Imbert et al. ()]{b38}\label{b38} ‘Adult patients presenting with pancytopenia: a reappraisal of underlying pathology and diagnostic procedures in 213 cases’. M Imbert , J Y Scoazec , J Y Mary , H Jouzult , H Rochant , C Sultan . \textit{Hematol Pathol} 1989. 3 (4) p. . \bibitem[Jain and Naniwadekar ()]{b40}\label{b40} ‘An etiological reappraisal ofpancytopenia -largest series reported to date from a single tertiary careteaching hospital’. A Jain , M Naniwadekar . \textit{BMC Hematology} 2013. 13 p. 10. \bibitem[Williams and Pancytopenia ()]{b0}\label{b0} ‘Aplastic anemia and Pure Red cell aplasia In: Wintrobe's Clinical Hematology’. D M Williams , Pancytopenia . \textit{Baltimore: William and Willkins}, 1993. p. . (10th edition) \bibitem[Khodke et al. ()]{b19}\label{b19} ‘Bone marrow examination in cases of pancytopenia’. K Khodke , S Marwah , G Buxi , R B Vadav , N K Chaturvedi . \textit{J Academy Clin Med} 2001. 2 p. . \bibitem[Jha et al. ()]{b7}\label{b7} ‘Bone marrow examination in cases of pancytopenia’. A Jha , G Sayami , R C Adhikari , A D Patna , R Jha . \textit{J Nepal Med Assoc} 2008. 47 p. . \bibitem[Nigam et al. ()]{b29}\label{b29} ‘Clinical, Haematological and Histomorphological Profile of Myelodysplastic Syndrome’. S Nigam , S Rani , T Sing . \textit{JAPI} 2001. 49 p. . \bibitem[Devi et al. ()]{b36}\label{b36} ‘Clinico-hematological Profile of Pancytopenia in Manipur’. P M Devi , R S Laishram , P S Sharma , A M Singh , M K Singh , Y Singh . \textit{India. Kuwait Medical Journal} 2008. 40 (3) p. . \bibitem[Chhabra et al. ()]{b24}\label{b24} ‘Clinicoaetiological profile of pancytopenia in paediatric practiceJournal’. A Chhabra , V Chandar , A Patel , H Chandra . \textit{Indian Academy of Clinical Medicine} 2012. 13 (4 l) p. . \bibitem[Clinicohaematological spectrum of pancytopenia in a tertiary care hospital J Postgrad Med Inst ()]{b10}\label{b10} ‘Clinicohaematological spectrum of pancytopenia in a tertiary care hospital’. \textit{J Postgrad Med Inst} 2013. 27 (2) p. . \bibitem[Kumar and Raghupathi ()]{b2}\label{b2} ‘Clinicohematologic analysis of pancytopenia study in a tertiary care centre’. D B Kumar , A R Raghupathi . \textit{Basic and Applied Pathology} 2012. 5 p. . \bibitem[Lakhey et al. ()]{b8}\label{b8} ‘Clinicohematological study of pancytopenia’. A Lakhey , O P Talwar , V K Singh , K C Sr . \textit{Journal of Pathology of Nepal} 2012. 2 p. . \bibitem[Valent et al. ()]{b31}\label{b31} ‘Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference’. P Valent , H-P Horny , J M Bennett , C Fonatsch , U Germing , Greenberg . \textit{Leukemia Research} 2007. (31) p. . \bibitem[Keisu and Ost ()]{b15}\label{b15} ‘Diagnosis in patients with severe pancytopenia suspected with severe aplastic anaemia’. M Keisu , A Ost . \textit{Eur J Haematol} 1990. 45 p. . \bibitem[Schroeder et al. ()]{b34}\label{b34} ‘Distinguishing myelodysplastic syndrome (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients’. T Schroeder , L Ruf , A Bernhardt , B Hildebrandt , M Aivado , C Aul . \textit{Ann Oncol} 2010. 21 (11) p. . \bibitem[Eivazi-Ziaei et al. ()]{b26}\label{b26} ‘Estimation of the Diagnostic Value of Myeloperoxidase Index and Lactate Dehydrogenase in Megaloblastic Anaemia’. J Eivazi-Ziaei , S Dastgiri , Z Sanaat . \textit{Journal of Clinical and Diagnostic Research} 2007. 1 (5) p. . \bibitem[Parmar et al. ()]{b21}\label{b21} ‘Etiological evaluation of Pancytopenia with special emphasis on megaloblastic anemia’. J K Parmar , S Sheikh , P Vidja . \textit{Paripex,Indian journal of research} 2013. 3 (4) p. . \bibitem[Pathak et al. ()]{b12}\label{b12} ‘Evaluation of bone marrow in patients with pancytopenia’. R Pathak , A Jha , G Sayami . \textit{Journal of Pathology of Nepal} 2012. 2 p. . \bibitem[Valent et al.]{b32}\label{b32} ‘Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS’. P Valent , B J Bain , J M Bennett , F Wimazal , W R Sperr , G Mufti , H P Horny . \textit{Leukemia Research} (36) p. . \bibitem[International agranulocytosis and aplastic anaemia study. Incidence of aplastic anaemia: the relevance of diagnostic criteria Blood ()]{b4}\label{b4} ‘International agranulocytosis and aplastic anaemia study. Incidence of aplastic anaemia: the relevance of diagnostic criteria’. \textit{Blood} 1987. 70 p. . \bibitem[Pudasaini et al. ()]{b42}\label{b42} ‘Interpretation of bone marrow aspiration in hematological disorder’. S Pudasaini , Kbr Prasad , S K Rauniyar , R Shrestha , K Gautam , R Pathak , S Koirala , U Manandhar , B Shrestha . \textit{J of Pathology of Nepal} 2012. 2 p. . \bibitem[Kwok et al. ()]{b33}\label{b33} ‘MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance’. B Kwok , J M Hall , J S Witte , Y Xu , P Reddy , K Lin , R Flamholz , B Dabbas , A Yung , J Al-Hafidh , E Balmert , C Vaupel , E Haderc , M J Mcginniss , S A Nahas , J Kines , R Bejar . \textit{BLOOD} 2015. 126 (21) p. . \bibitem[Kumar et al. ()]{b14}\label{b14} ‘Pancytopenia -a six year study’. R Kumar , S P Kalra , H Kumar , A C Anand , H Madan . \textit{J Assoc PhysIndia} 2001. 49 p. . \bibitem[Hossain et al. ()]{b5}\label{b5} ‘Pancytopenia -A study of 50 cases’. M A Hossain , A K Akond , M K Chowdhary . \textit{Bangladesh Journal of Pathology} 1992. 1 p. . \bibitem[Para and Para ()]{b25}\label{b25} ‘Pancytopenia -a study of 58 cases’. R Para , S Para . \textit{Journal of Evolution of Medical and Dental Sciences} 2013. 2 (45) p. . \bibitem[Jan et al. ()]{b11}\label{b11} ‘Pancytopenia in children: A 6-year spectrum of patients admitted to Pediatric Department of Rehman Medical Institute, Peshawar’. A Z Jan , B Zahid , S Ahmad , Z Gul . \textit{Pak J Med Sci} 2013. 29 (5) p. . \bibitem[Sarode et al. ()]{b30}\label{b30} ‘Pancytopenia in nutritional megaloblastic anemia. A study from north-west India’. R Sarode , G Garewal , N Marwaha . \textit{Trop Geogr Med} 1989. 41 p. . \bibitem[Savage et al. ()]{b16}\label{b16} ‘Pancytopenia in Zimbabwe’. D G Savage , R H Allen , I T Gangaidzo . \textit{Am J Med Sci} 1999. 317 p. . \bibitem[Tilak and Jain ()]{b18}\label{b18} ‘Pancytopenia-A Clinco-hematologic analysis of 77cases’. V Tilak , R Jain . \textit{Indian J Pathol Microbiol} 1992. 42 p. . \bibitem[Khunger et al. ()]{b20}\label{b20} ‘Pancytopenia-A Clinico-hematological study of 200 cases’. J M Khunger , S Arculselvi , U Sharma , S Ranga , V H Talib . \textit{Indian J Pathol Microbiol} 2002. 45 p. . \bibitem[Nigam et al. ()]{b22}\label{b22} ‘Pancytopenia-clinico-haematological studies of bone marrow examination’. R K Nigam , R Chaudhary , R Malik , D Gour , A Shrivastava , A Tripathi , R Ahirwar , R Jain . \textit{Journal of Evolution of Medical and Dental Sciences} 2013. 2 (7) p. . \bibitem[Ishtiaq et al. ()]{b41}\label{b41} ‘Patterns of pancytopenia patients in a general medical ward and a proposed diagnostic approach’. O Ishtiaq , H Z Baqai , F Anwer , N Hussian . \textit{J Ayub Med Coll Abbottabad} 2004. 1 p. . \bibitem[Meittinen ()]{b1}\label{b1} ‘Proportion of disease caused or prevented by a given exposured, trait or intervention’. O S Meittinen . \textit{Am J Epidemiol} 1974. 99 p. 325. \bibitem[Busque et al. ()]{b35}\label{b35} ‘Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis’. L Busque , J P Patel , M E Figueroa . \textit{Nat Genet} 2012. 44 (11) p. . \bibitem[Gupta et al. ()]{b39}\label{b39} ‘Red cell indices for distinguishing macrocytosis of aplastic anemia and megaloblastic anemia’. P K Gupta , R Saxena , A S Karan , V P Choudhary . \textit{Indian J Pathol Microbiol} 2003. 46 (3) p. . \bibitem[Varma and Dash ()]{b13}\label{b13} ‘S: Reppraisal of underlying pathology in adult patients presenting with pancytopenia’. N Varma , Dash . \textit{Trop Geogr Med} 1992. 44 p. . \bibitem[Cucuianu et al.]{b27}\label{b27} \textit{Serum lactate dehydrogenase and alkaline phosphatase activities and serum cholesterol level in bone marrow blood}, A Cucuianu , I Trif , M Cucuianu . \bibitem[Niazi and Raziq ()]{b6}\label{b6} \textit{The incidence of underlying pathology in pancytopenia}, M Niazi , F Raziq . 2004. p. . (Journal of postgraduate medical institute (JPMI)) \end{bibitemlist} \end{document}